Summary
Boston Scientific Corporation (BSX) has filed an 8-K report detailing changes to executive and director compensation related to the COVID-19 pandemic. Initially, in April 2020, the company announced temporary base salary reductions for its executive officers for up to six months due to pandemic-related uncertainty. This filing updates that policy, indicating a positive business outlook driven by stronger-than-expected second-quarter results and increased procedure volumes. As a result, the base salary reductions for most executive officers, excluding the CEO, will terminate in August 2020 after a four-month period. These executives will revert to 100 percent of their base salary. However, CEO Michael Mahoney will continue his 99 percent salary reduction through October 11, 2020, receiving only benefits-essential payments. Additionally, the annual cash retainer for non-employee directors will remain at 50 percent of the approved amount.
Key Highlights
- 1Restoration of executive officer base salaries (excluding CEO) effective August 2020.
- 2CEO Michael Mahoney continues a 99% base salary reduction until October 11, 2020.
- 3Temporary salary reductions were implemented in April 2020 due to COVID-19 uncertainty.
- 4The decision to restore salaries is driven by stronger-than-expected Q2 business results and procedure volumes.
- 5Non-employee director cash retainers remain reduced by 50%.
- 6The filing reflects a positive outlook and recovery trend for Boston Scientific.